NHS urged to implement annual checks for millions with PMOS

A condition that touches the lives of roughly one in eight women in Britain remains stubbornly difficult to diagnose. Polyendocrine metabolic ovarian syndrome—renamed just last year from the more familiar polycystic ovary syndrome to capture its wider effects on the body—affects somewhere between three and four million British women, yet many spend years without a clear answer for what is happening to them. Now the health regulator NICE is pushing the NHS to implement a simple but potentially transformative change: annual checks for women with the condition, designed to catch both the immediate symptoms and the serious long-term risks that often go unmonitored.

The condition announces itself in different ways. Irregular periods, excessive hair growth, weight gain—these are the hallmarks most people recognize. But PMOS is far more complicated than its surface symptoms suggest. It is a leading cause of infertility among women. It carries significant risk for diabetes and heart disease. It shapes mental health, with depression and anxiety appearing frequently in those who live with it. Yet because the condition is so often missed or managed inconsistently across different NHS services, many women suffer in silence, their symptoms dismissed or attributed to something else entirely.

The new guidance from NICE addresses this fragmentation head-on. The recommended annual reviews would look beyond the obvious signs to monitor for those longer-term complications—the metabolic and cardiovascular risks that can develop quietly over years. The regulator is also clear about what should not be offered: laser and light therapies for hair reduction, given their cost relative to benefit. But the focus is on what should be done: faster diagnosis, better consistency, and earlier intervention. Lifestyle support—changes to diet, exercise, sleep, and mental health care—alongside existing treatments like hormone therapy and fertility drugs, can help prevent more serious illness from taking hold.

Sharon Manship knows the cost of delay. She lived with PMOS for three decades before the condition was properly named and understood. When she first sought help in her early twenties, she was turned away repeatedly. Doctors told her that what she was experiencing was simply the reality of being a woman. It took more than a decade before she received a diagnosis, in her mid-thirties. She was part of the committee that shaped these new guidelines, and her hope is straightforward: that the next generation of women will not have to endure what she endured. "My hope is that with this new guideline, people with PMOS will be taken seriously, diagnosed earlier and provided with evidence-based support and care from healthcare professionals from the outset, rather than having to go what I went through," she said.

The guidance also acknowledges that PMOS does not follow a single pattern. It appears to be more common in women of Black, Asian, and mixed ethnicity, and healthcare professionals are being urged to keep this in mind when assessing symptoms. The condition should not be dismissed in women who have already gone through menopause, either—a reminder that PMOS is not simply a reproductive issue but a lifelong metabolic one.

Marie Anne Ledingham, a consultant clinical advisor at NICE, described the annual review recommendation as an important step toward consistency. "This new guideline will help improve consistency of care, increase awareness of the condition, and support earlier diagnosis and management," she said. The draft guidance is now open for consultation until mid-August, with feedback invited from healthcare professionals, patients, and the public. NICE expects to publish the final version in December 2026, at which point the NHS will begin the work of implementing these checks across the country. For millions of women who have waited far too long for answers, that timeline cannot come soon enough.